Thorne Research, Inc. Challenges the Validity of U.S. Patent of Pharmaceutical Compositions of Nicotinamide Riboside

NEW YORK, Dec. 2, 2020 /PRNewswire/ -- Thorne Research, Inc., yesterday filed a petition for inter partes review at the U.S. Patent Trial and Appeal Board to challenge Claim 2 of U.S. Patent No. 8,383,086, which relates to pharmaceutical compositions of nicotinamide riboside.  The owner of U.S. Patent No. 8,383,086 is Dartmouth College, which has licensed the patent's rights to ChromaDex, Inc.

U.S. Patent No. 8,383,086 has been previously challenged before the U.S. Patent Trial and Appeal Board by Elysium Health, Inc., which resulted in the cancellation of all of the patent's issued claims except for Claim 2.  Thorne Research's petition for inter partes review uses a different legal strategy to challenge Claim 2, and Thorne is confident in the strength of the legal arguments presented in its petition.

About Thorne
Thorne is the leader in providing medical practitioners, athletes, and consumers with innovative health solutions of the highest quality and caliber. The only testing and vitamin/supplement brand to be A1 TGA Certified, Thorne exceeds the strictest quality standards. The company's reputation and science-backed approach is the reason Thorne is one of the most trusted brands by both healthcare professionals and people around the world. For more information visit https://www.thorne.com.

CONTACT:
Edelman
[email protected]  

SOURCE Thorne Research, Inc.